Какова цена за VIA Pharmaceuticals, Inc. (VIAP)

Цена за VIA Pharmaceuticals, Inc. (VIAP) Это $0.0005

Какова рыночная капитализация для VIA Pharmaceuticals, Inc. (VIAP)

Рыночная капитализация для VIA Pharmaceuticals, Inc. (VIAP) Это $10.28K

VIA Pharmaceuticals, Inc. (VIAP) Дивидендная доходность

VIA Pharmaceuticals, Inc. is an emerging biotechnology company primarily focused on discovering and advancing therapeutic compounds for cardiovascular and metabolic disorders. The firm is building a portfolio of small-molecule drug candidates designed to tackle the root causes of these health issues, such as vascular inflammation, elevated cholesterol and triglyceride levels, and insulin resistance or diabetes. Notable candidates in their development pipeline include: VIA-3196: A liver-specific thyroid hormone receptor (THR) beta agonist, poised for Phase 1 clinical studies. This drug aims to mitigate dyslipidemia, addressing high LDL cholesterol, elevated triglycerides, and Lp(a) levels. A Diacylglycerol Acyl Transferase 1 (DGAT1) inhibitor: Currently in preclinical development for treating type 2 diabetes, with promising potential for weight management and other lipid disorders. VIA-2291: A 5-Lipoxygenase inhibitor that has successfully completed its third Phase 2 clinical trial. Its purpose is to target atherosclerotic plaque, a significant contributor to heart attacks, strokes, and various other vascular diseases. VIA Pharmaceuticals has also forged two research, development, and commercialization agreements with Hoffman-LaRoche Inc. and Hoffman-LaRoche Ltd. These collaborations pertain to their THR beta agonist program and several compounds from their preclinical DGAT1 metabolic disorders initiative. Established in 2004, the company's headquarters are located in San Francisco, California.

Год	Дивидендная доходность	Изменить
Недостаточно данных для указанных дат.

Год

Дивидендная доходность

Изменить

Недостаточно данных для указанных дат.

Компания	Дивидендная доходность	Страна
Royalty Pharma plc RPRX.US	1.56%	US
Swedish Orphan Biovitrum AB SOBI.ST	0.00%	SE
Ipsen S.A. IPN.PA	0.00%	FR
Recordati Industria Chimica e Farmaceutica S.p.A. REC.MI	0.00%	IT
Corcept Therapeutics Incorporated CORT.US	0.00%	US

Компания

Дивидендная доходность

Страна